スフィンゴシン1リン酸受容体（S1PR）モジュレーター医薬品の世界市場レポート 2025年

スフィンゴシン1リン酸受容体（S1PR）モジュレーター医薬品市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）6.0％で32億8,000万米ドルに成長します。予測期間の成長は、注射剤よりも経口療法への需要の高まり、自己免疫疾患の有病率の増加、世界のヘルスケア支出の増加、多発性硬化症などの疾患に対する認識と診断の高まり、自己免疫疾患に罹患しやすい老年人口の増加などに起因すると考えられます。予測期間における主な動向としては、受容体選択性の進歩、新規適応症の承認、リアルワールドエビデンス（RWE）の統合、ドラッグデリバリーの技術進歩、経口療法へのシフト、戦略的提携、買収などが挙げられます。

自己免疫疾患の有病率の増加は、スフィンゴシン1リン酸受容体（S1PR）モジュレーター医薬品市場の拡大を促進すると予想されます。自己免疫疾患は、免疫系が誤って身体の健康な細胞を攻撃し、炎症や組織損傷を引き起こすことで発症します。遺伝、環境的誘因、ライフスタイルの変化、診断能力の向上などの要因が、これらの疾患の発生率の増加に寄与しています。S1PR調節薬は、免疫細胞の遊走を調節し、多発性硬化症や潰瘍性大腸炎などの自己免疫疾患における炎症を抑えるのに役立ちます。例えば、2024年5月、米国を拠点とする保健統計機関National Center for Health Statistics（NCHS）が発表したデータによると、米国の18歳以上の成人における現在の喘息の有病率は、2021年の8.4％から2022年には8.7％に増加しました。さらに、同じ年齢層の成人の過去12ヵ月以内の喘息エピソードの発生率は、2021年の3.3％から2022年には3.7％に上昇しました。その結果、自己免疫疾患の有病率の上昇がS1PRモジュレーター医薬品市場の成長に拍車をかけています。

S1PR調節薬市場の主要企業は、患者のコンプライアンスを改善し、薬効を高め、自己免疫疾患の管理におけるこれらの薬剤の治療可能性を拡大するために、経口治療などの革新的な治療法の開発を重視しています。経口治療は、錠剤やタブレットの形で薬を投与するもので、患者に便利で非侵襲的な治療オプションを提供します。例えば、2022年3月、米国の製薬・バイオテクノロジー企業であるファイザーは、潰瘍性大腸炎患者を対象としたエトラシモドの第3相臨床試験の良好な結果を発表しました。この薬剤は主要評価項目と主要副次的評価項目を達成し、寛解率、内視鏡的転帰、症状緩和において有意な改善を示しました。これらの結果は、中等度から重度の潰瘍性大腸炎に対する新たな治療選択肢としてのエトラシモドの可能性を強調するものです。ファイザーは、免疫炎症性疾患のポートフォリオと革新的なヘルスケアソリューションへのコミットメントを強化し、薬事申請を進める予定です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界スフィンゴシン1リン酸受容体（S1PR）モジュレーター医薬品 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のスフィンゴシン1リン酸受容体（S1PR）モジュレーター医薬品市場：成長率分析
• 世界のスフィンゴシン1リン酸受容体（S1PR）モジュレーター医薬品市場の実績：規模と成長, 2019-2024
• 世界のスフィンゴシン1リン酸受容体（S1PR）モジュレーター医薬品市場の予測：規模と成長, 2024-2029, 2034F
• 世界スフィンゴシン1リン酸受容体（S1PR）モジュレーター医薬品総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のスフィンゴシン1リン酸受容体（S1PR）モジュレーター医薬品市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• フィンゴリモド
• オザニモド
• 世界のスフィンゴシン1リン酸受容体（S1PR）モジュレーター医薬品市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• トピック
• 世界のスフィンゴシン1リン酸受容体（S1PR）モジュレーター医薬品市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 多発性硬化症
• 心血管疾患
• 移植拒絶反応
• 世界のスフィンゴシン1リン酸受容体（S1PR）モジュレーター医薬品市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• リハビリテーションセンター
• 小売薬局
• 世界のスフィンゴシン1リン酸受容体（S1PR）モジュレーター医薬品市場フィンゴリモドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ブランド処方
• ジェネリック医薬品
• 世界のスフィンゴシン1リン酸受容体（S1PR）モジュレーター医薬品市場オザニモドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口カプセル
• その他の処方

第7章 地域別・国別分析

• 世界のスフィンゴシン1リン酸受容体（S1PR）モジュレーター医薬品市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のスフィンゴシン1リン酸受容体（S1PR）モジュレーター医薬品市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• スフィンゴシン1リン酸受容体（S1PR）モジュレーター医薬品市場：競合情勢
• スフィンゴシン1リン酸受容体（S1PR）モジュレーター医薬品市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis International AG
• Biogen Inc.
• Eisai Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Ono Pharmaceutical Co. Ltd.
• Actelion Pharmaceuticals Ltd.
• KYORIN Pharmaceutical Co. Ltd.
• Vanda Pharmaceuticals Inc.
• Celgene Corporation
• Ventyx Biosciences Inc.
• Idorsia Pharmaceuticals Ltd.
• Cayman Chemical Company
• Juvise Pharmaceuticals
• Priothera Limited
• Arena Pharmaceuticals

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• スフィンゴシン1リン酸受容体（S1PR）モジュレーター医薬品市場2029：新たな機会を提供する国
• スフィンゴシン1リン酸受容体（S1PR）モジュレーター医薬品市場2029：新たな機会を提供するセグメント
• スフィンゴシン1リン酸受容体（S1PR）モジュレーター医薬品市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Sphingosine 1 phosphate receptor (S1PR) modulator drugs are a class of therapeutic agents that specifically target sphingosine-1-phosphate (S1P) receptors, a family of G-protein-coupled receptors involved in essential cellular processes. These drugs regulate the activity of S1P receptors, which play a crucial role in immune cell trafficking, vascular function, and inflammation.

The primary types of sphingosine 1 phosphate receptor (S1PR) modulator drugs include fingolimod and ozanimod. Fingolimod is an oral medication used for treating multiple sclerosis (MS) by modulating the immune system to prevent nerve damage associated with the disease. These drugs are available in different routes of administration, including oral, injectable, and topical forms, and are used for treating multiple sclerosis, cardiovascular diseases, and transplant rejection. Their primary end-users include hospitals, rehabilitation centers, and retail pharmacies.

The sphingosine 1 phosphate receptor (S1PR) modulator drugs market research report is one of a series of new reports from The Business Research Company that provides sphingosine 1 phosphate receptor (S1PR) modulator drugs market statistics, including the sphingosine 1 phosphate receptor (S1PR) modulator drugs industry global market size, regional shares, competitors with the sphingosine 1 phosphate receptor (S1PR) modulator drugs market share, detailed sphingosine 1 phosphate receptor (S1PR) modulator drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the sphingosine 1 phosphate receptor (S1PR) modulator drugs industry. This sphingosine 1 phosphate receptor (S1PR) modulator drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The sphingosine 1 phosphate receptor (S1PR) modulator drugs market size has grown strongly in recent years. It will grow from $2.44 billion in 2024 to $2.60 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to the increasing prevalence of autoimmune diseases, greater investment in autoimmune drug development, the expansion of treatment indications, rising awareness of autoimmune disease management, and higher healthcare expenditure.

The sphingosine 1 phosphate receptor (S1PR) modulator drugs market size is expected to see strong growth in the next few years. It will grow to $3.28 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to growing demand for oral therapies over injectables, increasing prevalence of autoimmune diseases, rising healthcare expenditure globally, growth in awareness and diagnosis of conditions such as multiple sclerosis, and rising geriatric population prone to autoimmune diseases. Major trends in the forecast period include advancements in receptor selectivity, regulatory approvals for new indications, integration of real-world evidence (RWE), technological advancements in drug delivery, a shift toward oral therapies, strategic collaborations, and acquisitions.

The increasing prevalence of autoimmune diseases is expected to drive the expansion of the sphingosine 1-phosphate receptor (S1PR) modulator drugs market. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells, leading to inflammation and tissue damage. Factors such as genetics, environmental triggers, lifestyle changes, and improved diagnostic capabilities contribute to the growing incidence of these conditions. S1PR modulator drugs help regulate immune cell migration, reducing inflammation in autoimmune diseases such as multiple sclerosis and ulcerative colitis. For example, in May 2024, data published by the National Center for Health Statistics (NCHS), a US-based health statistics agency, indicated that the prevalence of current asthma among adults aged 18 and over in the United States increased from 8.4% in 2021 to 8.7% in 2022. Additionally, the incidence of asthma episodes within the past 12 months for adults in the same age group rose from 3.3% in 2021 to 3.7% in 2022. As a result, the rising prevalence of autoimmune diseases is fueling the growth of the S1PR modulator drugs market.

Leading companies in the S1PR modulator drugs market are emphasizing the development of innovative therapies, such as oral treatments, to improve patient compliance, enhance drug efficacy, and expand the therapeutic potential of these medications in managing autoimmune diseases. Oral therapy involves administering medications in pill or tablet form, providing a convenient and non-invasive treatment option for patients. For instance, in March 2022, Pfizer, a US-based pharmaceutical and biotechnology company, announced positive phase 3 trial results for etrasimod in ulcerative colitis patients. The drug met its primary and key secondary endpoints, demonstrating significant improvements in remission rates, endoscopic outcomes, and symptom relief. These results highlight etrasimod's potential as a new treatment option for moderate-to-severe ulcerative colitis. Pfizer plans to advance regulatory submissions, reinforcing its immuno-inflammatory disease portfolio and commitment to innovative healthcare solutions.

In December 2023, Vanda Pharmaceuticals, a US-based pharmaceutical company, acquired the U.S. and Canadian rights to PONVORY from Actelion Pharmaceuticals Ltd. for an undisclosed amount. This acquisition strengthens Vanda's portfolio by adding an innovative therapy for relapsing multiple sclerosis (MS), a condition with increasing prevalence and a significant unmet medical need. Actelion Pharmaceuticals Ltd., a Switzerland-based biopharmaceutical company, specializes in developing sphingosine 1-phosphate receptor (S1PR) modulator drugs for various diseases.

Major players in the sphingosine 1 phosphate receptor (s1pr) modulator drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb Company, Novartis International AG, Biogen Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Ono Pharmaceutical Co. Ltd., Actelion Pharmaceuticals Ltd., KYORIN Pharmaceutical Co. Ltd., Vanda Pharmaceuticals Inc., Celgene Corporation, Ventyx Biosciences Inc., Idorsia Pharmaceuticals Ltd., Cayman Chemical Company, Juvise Pharmaceuticals, Priothera Limited, and Arena Pharmaceuticals.

Asia-Pacific was the largest region in the sphingosine 1 phosphate receptor (S1PT) modulator drugs market in 2024. The regions covered in sphingosine 1 phosphate receptor (S1PR) modulator drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sphingosine 1 phosphate receptor (S1PR) modulator drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sphingosine 1 phosphate receptor (S1PR) modulator drugs market consists of sales of non-selective S1PR modulators, selective S1PR1 modulators, and next-generation and experimental S1PR modulators. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on sphingosine 1 phosphate receptor (s1pr) modulator drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for sphingosine 1 phosphate receptor (s1pr) modulator drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sphingosine 1 phosphate receptor (s1pr) modulator drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Fingolimod; Ozanimod
• 2) By Route Of Administration: Oral; Injectable; Topical
• 3) By Application: Multiple Sclerosis; Cardiovascular Diseases; Transplant Rejection
• 4) By End User: Hospital; Rehabilitation Centres; Retail Pharmacies
• Subsegments:
• 1) By Fingolimod: Branded Formulations; Generic Formulations
• 2) By Ozanimod: Oral Capsules; Other Formulations
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Bristol Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Characteristics

3. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Trends And Strategies

4. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Growth Rate Analysis
• 5.4. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Total Addressable Market (TAM)

6. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Segmentation

• 6.1. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fingolimod
• Ozanimod
• 6.2. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Topical
• 6.3. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Multiple Sclerosis
• Cardiovascular Diseases
• Transplant Rejection
• 6.4. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Rehabilitation Centres
• Retail Pharmacies
• 6.5. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Sub-Segmentation Of Fingolimod, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Branded Formulations
• Generic Formulations
• 6.6. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Sub-Segmentation Of Ozanimod, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Capsules
• Other Formulations

7. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Regional And Country Analysis

• 7.1. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 8.1. Asia-Pacific Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 9.1. China Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• 9.2. China Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 10.1. India Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 11.1. Japan Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• 11.2. Japan Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 12.1. Australia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 13.1. Indonesia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 14.1. South Korea Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• 14.2. South Korea Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 15.1. Western Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• 15.2. Western Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 16.1. UK Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 17.1. Germany Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 18.1. France Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 19.1. Italy Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 20.1. Spain Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 21.1. Eastern Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• 21.2. Eastern Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 22.1. Russia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 23.1. North America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• 23.2. North America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 24.1. USA Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• 24.2. USA Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 25.1. Canada Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• 25.2. Canada Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 26.1. South America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• 26.2. South America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 27.1. Brazil Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 28.1. Middle East Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• 28.2. Middle East Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

• 29.1. Africa Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
• 29.2. Africa Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Competitive Landscape And Company Profiles

• 30.1. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Competitive Landscape
• 30.2. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Other Major And Innovative Companies

• 31.1. Novartis International AG
• 31.2. Biogen Inc.
• 31.3. Eisai Co. Ltd.
• 31.4. Sun Pharmaceutical Industries Ltd.
• 31.5. Ono Pharmaceutical Co. Ltd.
• 31.6. Actelion Pharmaceuticals Ltd.
• 31.7. KYORIN Pharmaceutical Co. Ltd.
• 31.8. Vanda Pharmaceuticals Inc.
• 31.9. Celgene Corporation
• 31.10. Ventyx Biosciences Inc.
• 31.11. Idorsia Pharmaceuticals Ltd.
• 31.12. Cayman Chemical Company
• 31.13. Juvise Pharmaceuticals
• 31.14. Priothera Limited
• 31.15. Arena Pharmaceuticals

32. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

34. Recent Developments In The Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

35. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer